TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$23.19 USD
+0.12 (0.52%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $23.18 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.19 USD
+0.12 (0.52%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $23.18 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Quanterix Corporation (QTRX) Surges 13.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Surges 22.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed at $15.48 in the latest trading session, marking a -1.46% move from the prior day.
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed the most recent trading day at $14.63, moving -1.48% from the previous trading session.
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, TG Therapeutics (TGTX) closed at $14.70, marking a -1.41% move from the previous day.
TG Therapeutics (TGTX) Stock Moves -0.6%: What You Should Know
by Zacks Equity Research
In the latest trading session, TG Therapeutics (TGTX) closed at $14.79, marking a -0.6% move from the previous day.
TG Therapeutics (TGTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -50% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Universal Health Services (UHS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 2.03% and 1.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed at $19.34 in the latest trading session, marking a +1.79% move from the prior day.
TG Therapeutics (TGTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed the most recent trading day at $18.43, moving -0.27% from the previous trading session.
TG Therapeutics (TGTX) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
In the latest trading session, TG Therapeutics (TGTX) closed at $14.50, marking a -0.89% move from the previous day.
TG Therapeutics (TGTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
TG Therapeutics (TGTX) closed at $13.20 in the latest trading session, marking a +0.61% move from the prior day.
TG Therapeutics (TGTX) Soars 8.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Company News for Dec 30, 2022
by Zacks Equity Research
Companies in The News Are: IMGN, TGTX, TSLA, MSFT
TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug
by Zacks Equity Research
The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.
Can TG Therapeutics (TGTX) Climb 155% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for TG Therapeutics (TGTX) points to a 154.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 Medical Products Stocks Navigating Industry Challenges (Revised)
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
Zacks Industry Outlook Highlights QuidelOrtho, Lantheus and TG Therapeutics
by Zacks Equity Research
QuidelOrtho, Lantheus and TG Therapeutics are part of Zacks Industry Outlook article.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
TG Therapeutics (TGTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.